🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⏳ Only 2 weeks left to submit your abstract for ESTRO 2025! Don’t miss the chance to showcase your research in #RadOnc. Submit now! 📅Deadline: 20 November 2024 🔗 bit.ly/3MtIXUQ #ESTRO25

Urgent need for evidence on the role of PCI and MRI surveillance in all stages of Small Cell Lung Cancer in the era of immunotherapy 👉Please consider enrolling patients in the EORTC PRIMALUNG trial to contribute to advancing outcomes sciencedirect.com/science/articl…

Role PCI SCLC uncertain in Immunotherapy era · ADRIATIC LSSCLC trial ↑↑OS/PFS w/Durva · Use PCI ↑↑ outcomes (strat factor) · PCI Yes ↑↑PFS 28 mo vs 9/OS NR vs 37mo Support ongoing trials EORTC PRIMALung & SWOG MAVERICK MRI surveillance +/- (HA)PCI sciencedirect.com/science/articl…

Interested in reading about the role of PCI in the era on immunotherapy ? 👉 please read our latest paper published in JTO & JTO CRR and 🙏🏽enrol patients in the PRIMALUNG EORTC and MAVERICK SWOG Cancer Research Network trials PDBrown

Join the ESTRO family 💪

📢 We’re renewing the funding of our Cancer Research UK Lung Cancer Centre of Excellence over the next five years, with up to £4m support from ScottishPower. Read more: bit.ly/496Mjrd Charles Swanton | CRUK Lung Centre | UCL | The Francis Crick Institute | CRUK Manchester Institute

Many thanks to Science and Innovation at Cancer Research UK for renewing the funding for our joint The Christie NHS Manchester Cancer Research Centre UCL Lung Cancer Centre of Excellence Looking forward to exciting collaborations leading to improvements in patients outcome in the next 5 years

Fabulous news and so well deserved Patty Diez Hes 💙 👏👏

🔥off the press👉 We have defined a new cardiac anatomical region at risk for radiotherapy The cardiac avoidance area is described and an atlas provided to facilitate implementation Kathryn Banfill 💙 The Christie NHS Manchester Cancer Research Centre jtocrr.org/article/S2666-…

Unlocking the power of real-world data in UK radiotherapy: overcoming barriers inc accessibility, quality, governance is key Streamlined processes, data science training, and prioritisation are essential steps RTphysics Manchester The Royal College of Radiologists Read more 👉sciencedirect.com/science/articl…

Wow! Quite a bit of work to do now reviewing these abstracts ! ESTRO

Great work Isabella Fornacon-Wood Thitikorn Nuamek (Pao) James Price and the extended team! This is a great ressource for the oncology community and beyond

Interested in digital health, clinical trials and inclusivity?👉this PhD may be for you findaphd.com/search/Project… [findaphd.com]

This link will take you straight to our project Applying digital healthcare initiatives to make cancer clinical trials more inclusive findaphd.com/search/Project…

🚨 Exciting news from The Christie NHS We have introduced a dose limit to the top of the heart for lung cancer patients. But does this mean higher doses to other thoracic organs? 🤔 👉 This new paper shows that’s NOT the case doi.org/10.1016/j.rado… RTphysics Manchester Radiotherapy & Oncology

An important article emphasizing the challenges in drug-radiotherapy trials Our CONCORDE platform is showcased as an exemplar of innovative and efficient trial design Science and Innovation at Cancer Research UK Leeds CTRU The authors call on Craig Teper and nick to endorse and support similar approaches

Intriguing, indeed ….

Great inaugural lecture Cynthia Eccles 💙 @cynthiaeccles.bsky.social and fantastic journey from Canada to MAHSC professorship 👏👏

📊 An International EORTC Survey on Stage III NSCLC resectability: ✅ Resectable: Smaller tumors, w/ single-station N2 Larger tumours, w/ max N1 ❌ Unresectable: Bulky/invasive N2, N3 T4 tumours, w/ multi-station N2 Results shaped a consensual definition: lungcancerjournal.info/article/S0169-…

There is no agreement on resectability for 👉 smaller tumours with multi-station N2, or larger tumours with single-station N2. 👉invasive T4-tumours with maximum single-station N2